Marker Therapeutics Inc MRKR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRKR is a good fit for your portfolio.
News
-
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
-
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
-
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Trading Information
- Previous Close Price
- $4.14
- Day Range
- $4.13–4.32
- 52-Week Range
- $0.76–9.68
- Bid/Ask
- $4.14 / $5.20
- Market Cap
- $37.30 Mil
- Volume/Avg
- 14,370 / 18,609
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- http//www.markertherapeutics.com
Valuation
|
Metric
|
MRKR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.62 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MRKR
Financial Strength
|
Metric
|
MRKR
|
|---|---|
Quick Ratio | 5.25 |
Current Ratio | 5.57 |
Interest Coverage | — |
Quick Ratio
MRKR
Profitability
|
Metric
|
MRKR
|
|---|---|
Return on Assets (Normalized) | −55.27% |
Return on Equity (Normalized) | −78.35% |
Return on Invested Capital (Normalized) | −74.32% |
Return on Assets
MRKR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jjjbhhmssw | Xbfdb | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xhpwrncd | Nnzfcq | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xqnjjzn | Wzkxql | $98.8 Bil | |
MRNA
| Moderna Inc | Jxfnfjwb | Jvvpp | $38.8 Bil | |
ARGX
| argenx SE ADR | Nnhpqtb | Ktd | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Flrpggyn | Vsyq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xqtjtnfgf | Wfyfccq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zbvwdygh | Lbzhyn | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yskjbdpxps | Kljshs | $12.4 Bil | |
INCY
| Incyte Corp | Vjtxdbg | Yplpcp | $11.9 Bil |